Craft
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
banner
Newron Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.

Stock Price

CHF8.3

2024-10-29

Market Capitalization

CHF164.8 M

2024-10-29

Revenue

€19.1 M

FY, 2025

CreditSafe Score

?
Score changed on Jun 07, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn more

Financial Statements

EURFY, 2018FY, 2019FY, 2020FY, 2021FY, 2022FY, 2023FY, 2024FY, 2025
Revenue4.0M7.0M5.3M5.8M6.1M9.1M51.4M19.1M
Cost of goods sold1.4M
Gross profit2.7M7.0M5.3M5.8M6.1M9.1M51.4M19.1M
Gross profit margin, %65.9%100.0%100.0%100.0%100.0%100.0%100.0%100.0%
Operating expense total17.3M27.9M23.2M18.0M19.2M20.6M25.0M23.7M
Depreciation and amortization47.0K147.0K162.0K165.0K64.0K168.0K151.0K
EBITDA(14.6M)(20.9M)(17.9M)(12.2M)(13.1M)(11.6M)26.3M(4.5M)
EBITDA margin, %-363.0%-296.9%-340.8%-211.6%-215.6%-127.7%51.3%-23.8%
EBIT(15.0M)(20.9M)(18.1M)(12.4M)(13.3M)(11.6M)26.2M(4.7M)
EBIT margin, %-372.1%-296.9%-343.6%-214.5%-218.3%-128.4%50.9%-24.6%
Interest income132.0K1.4M882.0K54.0K56.0K179.0K138.0K539.0K
Interest expense385.0K664.0K2.3M3.0M4.3M4.8M5.6M8.2M
Pre tax profit(15.0M)(20.2M)(19.6M)(14.9M)(17.5M)(16.2M)21.4M(12.4M)
Income tax expense16.0K45.0K1.4M17.0K21.0K24.0K5.6M885.0K
Net Income(15.0M)(20.2M)(21.0M)(14.9M)(17.5M)(16.2M)15.8M(13.2M)

Footer menu